Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-Current Debt (2018 - 2022)

Historic Non-Current Debt for Theravance Biopharma (TBPH) over the last 5 years, with Q2 2022 value amounting to $396.1 million.

  • Theravance Biopharma's Non-Current Debt rose 561.39% to $396.1 million in Q2 2022 from the same period last year, while for Jun 2022 it was $396.1 million, marking a year-over-year increase of 561.39%. This contributed to the annual value of $371.4 million for FY2021, which is 40.6% down from last year.
  • Latest data reveals that Theravance Biopharma reported Non-Current Debt of $396.1 million as of Q2 2022, which was up 561.39% from $384.2 million recorded in Q1 2022.
  • In the past 5 years, Theravance Biopharma's Non-Current Debt ranged from a high of $396.1 million in Q2 2022 and a low of $217.7 million during Q2 2019
  • Its 5-year average for Non-Current Debt is $326.3 million, with a median of $373.9 million in 2020.
  • Its Non-Current Debt has fluctuated over the past 5 years, first tumbled by 445.9% in 2019, then skyrocketed by 7318.38% in 2020.
  • Quarter analysis of 5 years shows Theravance Biopharma's Non-Current Debt stood at $229.5 million in 2018, then fell by 4.46% to $219.3 million in 2019, then soared by 70.03% to $372.9 million in 2020, then fell by 0.41% to $371.4 million in 2021, then grew by 6.67% to $396.1 million in 2022.
  • Its Non-Current Debt was $396.1 million in Q2 2022, compared to $384.2 million in Q1 2022 and $371.4 million in Q4 2021.